...
fhtx-img

Foghorn Therapeutics Inc, Common Stock

FHTX

NMQ

$5.3

-$0.48

(-8.3%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$343.57M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
452.27K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
3.15
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.7 L
$10.25 H
$5.3

About Foghorn Therapeutics Inc, Common Stock

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameFHTXSectorS&P500
1-Week Return-19.33%-2.27%-0.57%
1-Month Return-40.11%-3.96%1.21%
3-Month Return-45.47%-9.7%7.57%
6-Month Return-5.53%-3.37%11.45%
1-Year Return-4.16%3.71%28.48%
3-Year Return-71.47%3.8%29.52%
5-Year Return-70.75%39.78%90.66%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-430.00K1.32M19.23M34.16M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":1.26,"profit":true},{"date":"2021-12-31","value":3.86,"profit":true},{"date":"2022-12-31","value":56.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue1.79M57.72M7.51M19.23K109.69M[{"date":"2019-12-31","value":1.63,"profit":true},{"date":"2020-12-31","value":52.62,"profit":true},{"date":"2021-12-31","value":6.85,"profit":true},{"date":"2022-12-31","value":0.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(1.79M)(57.28M)(6.20M)19.21M(75.53M)[{"date":"2019-12-31","value":-9.33,"profit":false},{"date":"2020-12-31","value":-298.22,"profit":false},{"date":"2021-12-31","value":-32.26,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-393.23,"profit":false}]
Gross Margin(Infinity%)(13322.09%)(469.75%)99.90%(221.15%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-13335.43,"profit":false},{"date":"2021-12-31","value":-470.22,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-221.37,"profit":false}]
Operating Expenses51.08M68.96M102.05M136.37M142.06M[{"date":"2019-12-31","value":35.96,"profit":true},{"date":"2020-12-31","value":48.54,"profit":true},{"date":"2021-12-31","value":71.84,"profit":true},{"date":"2022-12-31","value":95.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(51.08M)(68.53M)(100.73M)(117.14M)(107.91M)[{"date":"2019-12-31","value":-5108400000,"profit":false},{"date":"2020-12-31","value":-6853100000,"profit":false},{"date":"2021-12-31","value":-10073400000,"profit":false},{"date":"2022-12-31","value":-11713700000,"profit":false},{"date":"2023-12-31","value":-10790600000,"profit":false}]
Total Non-Operating Income/Expense(89.00K)(247.00K)61.00K13.93M24.30M[{"date":"2019-12-31","value":-0.37,"profit":false},{"date":"2020-12-31","value":-1.02,"profit":false},{"date":"2021-12-31","value":0.25,"profit":true},{"date":"2022-12-31","value":57.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(51.13M)(68.80M)(101.32M)(108.88M)(94.20M)[{"date":"2019-12-31","value":-5112800000,"profit":false},{"date":"2020-12-31","value":-6880000000,"profit":false},{"date":"2021-12-31","value":-10132000000,"profit":false},{"date":"2022-12-31","value":-10888200000,"profit":false},{"date":"2023-12-31","value":-9420000000,"profit":false}]
Income Taxes540.00K979.00K1.91M(8.26K)4.23M[{"date":"2019-12-31","value":12.78,"profit":true},{"date":"2020-12-31","value":23.17,"profit":true},{"date":"2021-12-31","value":45.1,"profit":true},{"date":"2022-12-31","value":-0.2,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(51.67M)(69.78M)(103.23M)(108.87M)(98.43M)[{"date":"2019-12-31","value":-5166800000,"profit":false},{"date":"2020-12-31","value":-6977900000,"profit":false},{"date":"2021-12-31","value":-10322600000,"profit":false},{"date":"2022-12-31","value":-10887374500,"profit":false},{"date":"2023-12-31","value":-9842600000,"profit":false}]
Income From Continuous Operations(51.13M)(68.80M)(101.32M)(108.88M)(103.21M)[{"date":"2019-12-31","value":-5112800000,"profit":false},{"date":"2020-12-31","value":-6880000000,"profit":false},{"date":"2021-12-31","value":-10132000000,"profit":false},{"date":"2022-12-31","value":-10888200000,"profit":false},{"date":"2023-12-31","value":-10320600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(51.67M)(69.78M)(103.23M)(108.87M)(98.43M)[{"date":"2019-12-31","value":-5166800000,"profit":false},{"date":"2020-12-31","value":-6977900000,"profit":false},{"date":"2021-12-31","value":-10322600000,"profit":false},{"date":"2022-12-31","value":-10887374500,"profit":false},{"date":"2023-12-31","value":-9842600000,"profit":false}]
EPS (Diluted)-(6.27)(2.70)(2.62)(2.34)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-627,"profit":false},{"date":"2021-12-31","value":-270,"profit":false},{"date":"2022-12-31","value":-262,"profit":false},{"date":"2023-12-31","value":-234,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

FHTX
Cash Ratio 4.71
Current Ratio 4.77

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

FHTX
ROA (LTM) -20.45%
ROE (LTM) -470.38%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

FHTX
Debt Ratio Lower is generally better. Negative is bad. 1.09
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.09

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

FHTX
Trailing PE NM
Forward PE NM
P/S (TTM) 13.47
P/B 10.71
Price/FCF NM
EV/R 3.65
EV/Ebitda NM

FAQs

What is Foghorn Therapeutics Inc share price today?

Foghorn Therapeutics Inc (FHTX) share price today is $5.3

Can Indians buy Foghorn Therapeutics Inc shares?

Yes, Indians can buy shares of Foghorn Therapeutics Inc (FHTX) on Vested. To buy Foghorn Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FHTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Foghorn Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Foghorn Therapeutics Inc (FHTX) via the Vested app. You can start investing in Foghorn Therapeutics Inc (FHTX) with a minimum investment of $1.

How to invest in Foghorn Therapeutics Inc shares from India?

You can invest in shares of Foghorn Therapeutics Inc (FHTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in FHTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Foghorn Therapeutics Inc shares
What is Foghorn Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Foghorn Therapeutics Inc (FHTX) is $10.25. The 52-week low price of Foghorn Therapeutics Inc (FHTX) is $2.7.

What is Foghorn Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Foghorn Therapeutics Inc (FHTX) is

What is Foghorn Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Foghorn Therapeutics Inc (FHTX) is 10.71

What is Foghorn Therapeutics Inc dividend yield?

The dividend yield of Foghorn Therapeutics Inc (FHTX) is 0.00%

What is the Market Cap of Foghorn Therapeutics Inc?

The market capitalization of Foghorn Therapeutics Inc (FHTX) is $343.57M

What is Foghorn Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Foghorn Therapeutics Inc is FHTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top